ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants

Abbreviations

CDC: Centers for Disease Control and Prevention

ECDC: European Centre for Disease Prevention and Control

ESGE: European Society of Gastrointestinal Endoscopy

ESGENA: European Society of Gastroenterology and Endoscopy Nurses and Associates

FFP: filtering facepiece

HCP: healthcare professional

INAAT: isothermal nucleic acid amplification

IDSA: Infectious Diseases Society of America

IPC: infection prevention and control

PCR: polymerase chain reaction

PPE: personal protective equipment

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

WHO: World Health Organization

^* Co-first authors

Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2021

• References

• 1 Baden LR, El Sahly HM, Essink B. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403-416
• 2 Polack FP, Thomas SJ, Kitchin N. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-2615
• 3 Voysey M, Costa Clemens SA, Madhi SA. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397: 881-891
• 4 Thomas SJ, Moreira ED, Kitchin N. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021;
• 5 Sadoff J, Gray G, Vandebosch A. et al. Safety and efficacy of single-dose Ad26. COV2.S vaccine against Covid-19. N Engl J Med 2021; 384: 2187-2201
• 6 Lopez Bernal J, Andrews N, Gower C. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385: 585-594
• 7 European Centre for Disease Prevention and Control (ECDC). COVID-19 Vaccine Tracker [cited 2021 Oct 4]. Available from: https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
• 8 Bar-On YM, Goldberg Y, Mandel M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021; 385: 1393-1400
• 9 Krause PR, Fleming TR, Peto R. et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021; 398: 1377-1380
• 10 The WHO is right to call a temporary halt to COVID vaccine boosters. Nature 2021; 596: 317
• 11 World Health Organization. Rational use of personal protective equipment for COVID-19 and considerations during severe shortages. https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages
• 12 Ebigbo A, Karstenson JG, Bhat P. et al. Impact of the COVID-19 pandemic on gastrointestinal endoscopy in Africa. Endosc Int Open 2020; 8: E1097-E1101
• 13 Antonelli G, Karsensten JG, Bhat P. et al. Resuming endoscopy during COVID-19 pandemic: ESGE, WEO and WGO Joint Cascade Guideline for Resource Limited Settings. Endosc Int Open 2021; 9: E543-E551
• 14 Gralnek IM, Hassan C, Beilenhoff U. et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. Endoscopy 2020; 52: 483-490
• 15 Gralnek IM, Hassan C, Beilenhoff U. et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: An update on guidance during the post-lockdown phase and selected results from a membership survey. Endoscopy 2020; 52: 891-898
• 16 Suzuki T, Hayakawa K, Ainai A. et al. Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers. J Infect Chemother 2021; 27: 120-122
• 17 Ingram C, Downey V, Roe M. et al. COVID-19 prevention and control measures in workplace settings: a rapid review and meta-analysis. Int J Environ Res Public Health 2021; 18: 7847
• 18 World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected [cited 2020 Apr 3]. Available from: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125
• 19 Centers for Disease Control (CDC). Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [cited 2020 Apr 4]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html
• 20 Bartoszko JJ, Farooqi MAM, Alhazzani W. et al. Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: A systematic review and meta-analysis of randomized trials. Influenza Other Respir Viruses 2020; 14: 365-373
• 21 Naaber P, Tserel L, Kangro K. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021;
• 22 Goel RR, Painter MM, Apostolidis SA. et al. mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern. bioRxiv 457229 [Preprint] 2021;
• 23 Shrotri M, Navaratnam AMD, Nguyen V. et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 2021; 398: 385-387
• 24 Chemaitelly H, Tang P, Hasan MR. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med 2021;
• 25 Centers for Disease Control and Prevention (CDC). Why CDC measures vaccine effectiveness [cited 2020 Sep 4]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html
• 26 Gallais F, Gantner P, Bruel T. et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine 2021; 71: 103561
• 27 Gazit S, Shlezinger R, Perez G. et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv 21262415 [Preprint]
• 28 Antonelli M, Penfold RS, Merino J. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2021;
• 29 Bergwerk M, Gonen T, Lustig Y. et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021; 385: 1474-1484
• 30 Sultan S, Siddique SM, Singh S. et al. AGA Rapid Review and Guideline for SARS-CoV2 testing and endoscopy post-vaccination: 2021 Update. Gastroenterology 2021; 161: 1011-1029.e11
• 31 European Centre for Disease Prevention and Control (ECDC). Infection prevention and control for COVID-19 in healthcare settings – first update. https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-infection-prevention-and-control-healthcare-settings-march-2020.pdf
• 32 Hanson KE, Caliendo AM, Arias CA. et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: Serologic testing. Clin Infect Dis 2020;
• 33 Dinnes J, Deeks JJ, Adriano A. et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2020; 8: CD013705
• 34 McDade TW, Demonbreun AR, Sancilio A. et al. Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Sci Rep 2021; 11: 17325
• 35 Wang Z, Muecksch F, Schaefer-Babajew D. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021; 595: 426-431